STAT+: Key Senate committee considers a carveout for small biotech companies in drug pricing reforms
WASHINGTON — A key Senate panel is seriously considering a new policy that would soften the blow of drug pricing reform for small biotech companies, according to two sources familiar with the talks. But the concession isn’t likely to win over the biotech industry.
The change would be part of a package of broader drug pricing reforms from Senate Finance Committee Chairman Ron Wyden (D-Ore.), who promised, vaguely, to protect the smaller companies earlier this year. But the specifics of his policy have been unclear until now, as Democrats in both chambers of Congress look to include some kind of drug pricing reform in the massive government spending bill they’re debating in earnest.
Continue to STAT+ to read the full story…
